93
Participants
Start Date
April 30, 2016
Primary Completion Date
June 5, 2017
Study Completion Date
August 28, 2017
Visbiome Extra Strength
From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
Placebo
From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
7804 Weill Cornell Chelsea CRS, New York
Columbia Physicians and Surgeons CRS (30329), New York
7803 Weill Cornell Upton CRS, New York
Pittsburgh CRS (1001), Pittsburgh
6201 Penn Therapeutics CRS, Philadelphia
Johns Hopkins Adult AIDS CRS (201), Baltimore
Greensboro CRS (3203), Greensboro
Unc Aids Crs (3201), Chapel Hill
31788 Alabama CRS, Birmingham
Vanderbilt Therapeutics CRS (3652), Nashville
The Ohio State University AIDS CRS (2301), Columbus
Case CRS (2501), Cleveland
University of Cincinnati CRS (2401), Cincinnati
Northwestern University CRS (2701), Chicago
Rush University Medical Center (2702), Chicago
Washington University CRS (2101), St Louis
Trinity Health and Wellness Center CRS (31443), Dallas
Houston AIDS Research Team CRS (31473), Houston
University of Colorado Hospital CRS (6101), Aurora
UCLA CARE Center CRS (601), Los Angeles
701 University of California, San Diego AntiViral Research Center CRS, San Diego
801 University of California, San Francisco HIV/AIDS CRS, San Francisco
University of Washington AIDS CRS (1401), Seattle
31786 New Jersey Medical School Clinical Research Center CRS, Newark
Puerto Rico-AIDS CRS (5401), San Juan
Collaborators (1)
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Exegi Pharma, LLC
INDUSTRY
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NETWORK